HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and Therapy.

Abstract
Aim This update of the interdisciplinary S3 guideline on the Diagnosis, Therapy and Follow-up of Cervical Cancer (AWMF Registry No. 032/033OL) was published in March 2021. This updated guideline was funded by German Cancer Aid (Deutsche Krebshilfe) as part of the German Guideline Program in Oncology. The guideline was coordinated by the German Society of Gynecology and Obstetrics ( Deutsche Gesellschaft für Gynäkologie und Geburtshilfe , DGGG) and the Working Group on Gynecological Oncology ( Arbeitsgemeinschaft Gynäkologische Onkologie , AGO) of the German Cancer Society ( Deutsche Krebsgesellschaft , DKG). Method The process of updating the S3 guideline dating from 2014 was based on an appraisal of the available evidence using the criteria of evidence-based medicine, adaptations of existing evidence-based national and international guidelines or - if evidence was lacking - on a consensus of the specialists involved in compiling the update. After an initial review of the current literature was carried out according to a prescribed algorithm, several areas were identified which, in contrast to the predecessor version from September 2014, required new recommendations or statements which took account of more recently published literature and the appraisal of the new evidence. Recommendations The short version of this guideline consists of recommendations and statements on the epidemiology, screening, diagnostic workup and therapy of patients with cervical cancer. The most important new aspects included in this updated guideline include the newly published FIGO classification of 2018, the radical open surgery approach for cervical cancers up to FIGO stage IB1, and use of the sentinel lymph node technique for tumors ≤ 2 cm. Other changes include the use of PET-CT, new options in radiotherapy (e.g., intensity-modulated radiotherapy, image-guided adaptive brachytherapy), and drug therapies to treat recurrence or metastasis.
AuthorsMatthias W Beckmann, Frederik A Stübs, Martin C Koch, Peter Mallmann, Christian Dannecker, Anna Dietl, Anna Sevnina, Franziska Mergel, Laura Lotz, Carolin C Hack, Anne Ehret, Daniel Gantert, Franca Martignoni, Jan-Philipp Cieslik, Jan Menke, Olaf Ortmann, Carmen Stromberger, Karin Oechsle, Beate Hornemann, Friederike Mumm, Christoph Grimm, Alina Sturdza, Edward Wight, Kristina Loessl, Michael Golatta, Volker Hagen, Timm Dauelsberg, Ingo Diel, Karsten Münstedt, Eberhard Merz, Dirk Vordermark, Katja Lindel, Christian Wittekind, Volkmar Küppers, Ralph Lellé, Klaus Neis, Henrik Griesser, Birgit Pöschel, Manfred Steiner, Ulrich Freitag, Tobias Gilster, Alexander Schmittel, Michael Friedrich, Heidemarie Haase, Marion Gebhardt, Ludwig Kiesel, Michael Reinhardt, Michael Kreißl, Marianne Kloke, Lars-Christian Horn, Regina Wiedemann, Simone Marnitz, Anne Letsch, Isabella Zraik, Bernhard Mangold, Jochen Möckel, Céline Alt, Pauline Wimberger, Peter Hillemanns, Kerstin Paradies, Alexander Mustea, Dominik Denschlag, Ulla Henscher, Reina Tholen, Simone Wesselmann, Tanja Fehm
JournalGeburtshilfe und Frauenheilkunde (Geburtshilfe Frauenheilkd) Vol. 82 Issue 2 Pg. 139-180 (Feb 2022) ISSN: 0016-5751 [Print] Germany
PMID35169387 (Publication Type: Journal Article)
CopyrightThieme. All rights reserved.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: